En Es
Categorías

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological functions. The company also provides sequencing and array-based solutions for genetic analysis, as well as genotyping, NIPT and whole-genome sequencing services for government laboratories, hospitals, an ...
Productos Covid-19NoticiasResumen
Close

Covid-19 Illumina

Laboratorio clínico

SARS-CoV-2 NGS Test
Illumina COVIDSeq Test

The Illumina COVIDSeq Test is a high-throughput, next-generation sequencing test is intended for the detection of SARS-CoV-2 virus RNA in authorized countries and virus genome analysis for research use. This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19.
Mas detalles

SARS-CoV-2 (COVID-19) Test
Illumina COVIDSeq Test

The Illumina COVIDSeq Test is the first NGS test approved for use under the US Food and Drug Administration’s Emergency Use Authorization (EUA). This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19. The test can be run on the Illumina NovaSeq 6000 Sequencing System, NextSeq 500 Sequencing System, NextSeq 550 Sequencing System, or NextSeq 550Dx Instrument.
Mas detalles
Close

Noticias of Illumina

Illumina and Boehringer Ingelheim Partner to Develop Companion Diagnostics (CDx) for Cancer Treatment

20 Jan 2022
Illumina and Boehringer Ingelheim Partner to Develop Companion Diagnostics (CDx) for Cancer Treatment
Illumina Inc. (San Diego, CA, USA) has entered into a partnership with Boehringer Ingelheim (Ingelheim am Rhein, Germany; www.boehringer-ingelheim.com) to develop companion diagnostics (CDx) for several programs in the latter’s oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
Más info

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

20 Aug 2021
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test
Illumina, Inc. (San Diego, CA, USA) has acquired GRAIL (Menlo Park, CA, USA), a healthcare company focused on life-saving early detection of multiple cancers.
Más info
Close

Sobre Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological functions. The company also provides sequencing and array-based solutions for genetic analysis, as well as genotyping, NIPT and whole-genome sequencing services for government laboratories, hospitals, and reference laboratories, among others.
Facebook Twitter Google+ Linked in
Clinical NGS System

Clinical NGS System

Modelo: MiSeqDx System
Solicite información

Descripción:

The MiSeqDx System is the first FDA-cleared next-generation sequencing (NGS) platform for in vitro diagnostic (IVD) testing that provides accurate, reliable data for screening and diagnostic testing, including assays for cystic fibrosis testing. Designed specifically for clinical laboratories, it delivers a broad range of sequencing applications and provides an easy-to-use, automated workflow for obtaining comprehensive and reliable DNA sequencing results.

Etiquetas: [Laboratorio clínico]

Enviar un mensaje al proveedor

* Información requerida
* Email:
Para
Illumina (Clinical NGS System)
* Mensaje

Derecho de autor © 2000-2022 TradeMed.com. Todos los derechos reservados. | Términos y condiciones